%20Co.%2C%20Ltd.?token=pk_N6r40FsSTYeUvCEX-vHRYg&size=240&format=webp&fallback=404){kind=logo}
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a leading biopharmaceutical company based in China, focuses on innovative drug discovery and development. Founded in 2015, the company has rapidly established itself in the biotechnology sector, with its headquarters in Beijing and operational reach across major regions in China.
Specialising in monoclonal antibodies and gene editing technologies, Biocytogen is renowned for its unique animal models that facilitate advanced preclinical research. The company’s commitment to innovation has positioned it as a key player in the global biopharmaceutical landscape, with notable achievements in therapeutic development and collaborations with various research institutions.
With a strong emphasis on quality and scientific excellence, Biocytogen continues to drive advancements in the industry, contributing significantly to the future of healthcare solutions.
-15 vs industry average
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s score of 23 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Biocytogen Pharmaceuticals (Beijing) Co., Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s reported carbon emissions
In 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported total carbon emissions of approximately 23.9 million kg CO2e. This figure includes 741,070 kg CO2e from Scope 1 emissions and about 23.2 million kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Comparatively, in 2023, the organisation's emissions were approximately 23.5 million kg CO2e, with Scope 1 emissions at 923,770 kg CO2e and Scope 2 emissions at about 22.6 million kg CO2e. This indicates a slight increase in total emissions from 2023 to 2024. Biocytogen has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of defined reduction strategies suggests a need for further development in their climate action plans. Overall, while Biocytogen Pharmaceuticals is actively reporting its emissions, the lack of comprehensive Scope 3 data and formal reduction targets highlights an area for potential improvement in their sustainability efforts.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project